H. Xue

Knockdown of the long non-coding RNA CACNA1G-AS1 enhances cytotoxicity and apoptosis of human diffuse large B cell lymphoma by regulating miR-3160-5p

Yan Zhang, Xia Zhao, Shuxin Xiao, 2022, Experimental and therapeutic medicine.

Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B‐Cell lymphoma ‐results of a single center, retrospective cohort in China

Fanjing Jing, Lili Wang, Wei Song, 2022, Hematological oncology.

Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study

Peng Liu, Jing Li, Q. Zhan, 2022, Annals of Hematology.

Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial

Q. Cai, Mingzhi Zhang, Wei Song, 2022, American journal of hematology.

Penpulimab for Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter, Single-Arm, Pivotal Phase I/II Trial (AK105-201)

Ligen Liu, Jun Zhu, Yu Hu, 2022, Frontiers in Oncology.

DDGP followed by radiotherapy vs VIPD followed by radiotherapy in newly diagnosed early NK/T-cell lymphoma.

Yi Lu, Xiao-yan Feng, Mingzhi Zhang, 2022, Leukemia research.

Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: Extended follow‐up of the multicenter, single‐arm, Phase 2 study

Tongyu Lin, Jianda Hu, Weiwei Wang, 2021, International journal of cancer.

Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial.

K. Young, Zhaoming Li, Jieming Zhang, 2022, JAMA oncology.